Puma Biotechnology (PBYI) Enterprise Value (2011 - 2026)

Puma Biotechnology has reported Enterprise Value for 16 years, with the latest figure at -$101.5 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 8.99% year-over-year to -$101.5 million; the trailing twelve-month figure through Mar 2026 stood at -$101.5 million (down 8.99% YoY), and the FY2025 full-year result was -$97.5 million, down 40.9% from the prior year.
• Enterprise Value for Q1 2026 stood at -$101.5 million, down from -$97.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$52.8 million in Q2 2022, with the low at -$107.2 million in Q1 2024.
• Historically, Enterprise Value has averaged -$83.3 million across 5 years, with a median of -$85.0 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 46.55% — and 2024, when it slumped 50.47%.
• Puma Biotechnology's Enterprise Value stood at -$81.1 million in 2022, then retreated by 18.34% to -$95.9 million in 2023, then grew by 27.85% to -$69.2 million in 2024, then sank by 40.9% to -$97.5 million in 2025, then fell by 4.12% to -$101.5 million in 2026.
• The last three Enterprise Value figures came in at -$101.5 million (Q1 2026), -$97.5 million (Q4 2025), and -$55.6 million (Q3 2025), per Business Quant data.